Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review.
Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.
['Blomberg|Carl|C|', 'Nilsson|Jonas|J|', 'Holgersson|Georg|G|', 'Edlund|Per|P|', 'Bergqvist|Michael|M|', 'Adwall|Linda|L|', 'Ekman|Simon|S|', 'Brattström|Daniel|D|', 'Bergström|Stefan|S|']
D000971:Antineoplastic Combined Chemotherapy Protocols D003131:Combined Modality Therapy D018572:Disease-Free Survival D006801:Humans D008175:Lung Neoplasms D008654:Mesothelioma D000086002:Mesothelioma, Malignant D010166:Palliative Care D010997:Pleural Neoplasms D016032:Randomized Controlled Trials as Topic
randomized trials Malignant mesothelioma review